Dr. Radha Sekhar, Managing Director, Lotus Labs Pvt. Ltd. & Vice President, Global Clinical Operations, Teva Pharmaceuticals

On today’s episode of The Brand Called You, we have with us a very senior healthcare professional, Mrs. Radha Shekhar. Mrs. Shekhar is the founder and head of Lotus Laboratories and VP of global clinical operations at Teva Pharmaceuticals, both of which are top clinical research and pharma centres. She has published various research papers and also holds a PhD in Pharmacy. 

Talking about Lotus Laboratories, Mrs. Shekhar mentioned that internal clinics are spread out all over India. Teva Pharmaceuticals is the world’s largest generic drug company. It has given about 200 million prescriptions! Teva also provides direct employment to more than 4 thousand people! 

Mrs. Shekhar informed that her business is spread in Mumbai, Chennai, Bangalore, Goa, Noida and Florida. Mr. Garg and Mrs. Shekhar discussed the contribution of Indian Pharmacy to the world. They discussed the access to healthcare in remote areas, price control regime, export market and supply chain problems in Pandemic. She elucidated on gender balance and the striking inequality towards women in the workplace. 

Success to Mrs. Shekhar is achieving goals with integrity and along with her team. Her advice to the budding entrepreneurs is commendable!

Dr. Radha Sekhar, Managing Director, Lotus Labs Pvt. Ltd. & Vice President, Global Clinical Operations, Teva Pharmaceuticals



Ph. D., Pharmacy, Birla Institute of Technology, India
B. Pharm., Institute of Chemical Technology, Mumbai University, Distinction (6 th Rank)
Advanced Course in Pharmacokinetics, Kansas University, 1st Rank
Post Graduate Diploma in Biopharmaceutics and Pharmacokinetics, Bombay College of Pharmacy
Doctoral Research
I completed my Ph. D. in Pharmacy from Birla Institute of Technology, Ranchi. I worked with triazole based novel anti-tubercular compounds. Five NCE’s, each with two chiral centers were evaluated for their chemical and metabolic stability. The analytical method for the chemical stability and for the metabolic stability was validated. The compound which exhibited optimum stability was selected for further chiral separation and preparative scale chiral chromatography was used for the isolation of the four individual enantiomers. The chiral analytical method used was validated. Each of these four enantiomers were evaluated for their anti-tubercular property and
the most potent enantiomer was identified.
Current Role
Lotus Labs Pvt. Ltd., Bangalore (2003- Present)
Managing Director, Lotus Labs Pvt. Ltd.
Vice President, Global Clinical Operations, Teva Pharmaceuticals.
I am a Director on the Board of Lotus Labs Pvt. Ltd. and Teva India Pvt. Ltd.
Responsible for all activities pertaining to the Teva’s Clinical Research operations in India for both Lotus Labs and BEC – Teva’s clinical research center at Navi Mumbai. I joined Lotus Labs in 2003 as Chief of Analytical Services
and then worked as Sr Director – Quality Assurance before assuming responsibility as the Managing Director.
Read More
The clinical research support provided by the Indian operations form a vital link in Teva Pharmaceuticals R & operations both for the generic and specialty products. Both healthy human volunteer bioequivalence studies and patient-based PK or clinical end point studies are managed by our clinical research team. I have led Lotus through 115 successful regulatory inspections, which includes 51 USFDA inspections. This stands testimony to our scientific skills, integrity and excellent compliance to the various international regulatory requirements. With a total bed capacity of 338 beds and 40 LCMSMS machines across Navi Mumbai and Bangalore we are one of the largest CRO’s operating in India.







Notify of
Inline Feedbacks
View all comments

Featured Collection

Would love your thoughts, please comment.x
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.